Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Curr Vasc Pharmacol ; 17(6): 635-643, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-29866011

RESUMO

BACKGROUND: Triflusal has demonstrated an efficacy similar to aspirin in the prevention of vascular events in patients with acute myocardial infarction (ΜΙ) and ischaemic stroke but with less bleeding events. OBJECTIVE: We performed a randomised, multicentre, phase 4 clinical trial to compare the clinical efficacy and safety of triflusal versus aspirin, administered for 12 months in patients eligible to receive a cyclooxygenase-1 (COX-1) inhibitor. METHODS: Patients with stable coronary artery disease or with a history of non-cardioembolic ischaemic stroke were randomly assigned to receive either triflusal 300 mg twice or 600 mg once daily or aspirin 100 mg once daily for 12 months. The primary efficacy endpoint was the composite of: (a) ΜΙ, (b) stroke (ischaemic or haemorrhagic), or, (c) death from vascular causes for the entire follow-up period. The primary safety endpoints were the rate of bleeding events as defined by Bleeding Academic Research Consortium (BARC) criteria. RESULTS: At 12-month follow-up, an equivalent result was revealed between the triflusal (n=559) and aspirin (n=560) in primary efficacy endpoint. Specifically, the combined efficacy outcome rate (i.e. MI, stroke or death from vascular causes) difference was equal to -1.3% (95% confidence interval -1.1 to 3.5) and lied within the a-priori defined equivalence interval (p<0.001). Regarding the primary safety endpoints, patients on triflusal treatment were 50% less likely to develop bleeding events according to the BARC criteria, and especially any clinically overt sign of haemorrhage that requires diagnostic studies, hospitalisation or special treatment (BARC type 2). CONCLUSION: The efficacy of triflusal in the secondary prevention of vascular events is similar to aspirin when administered for 12 months. Importantly, triflusal significantly reduced the incidence of ΜΙ and showed a better safety profile compared with aspirin. (ASpirin versus Triflusal for Event Reduction In Atherothrombosis Secondary prevention, ASTERIAS trial; Clinical Trials.gov Identifier: NCT02616497).


Assuntos
Aspirina/uso terapêutico , Isquemia Encefálica/prevenção & controle , Doença da Artéria Coronariana/tratamento farmacológico , Inibidores de Ciclo-Oxigenase/uso terapêutico , Embolia Intracraniana/prevenção & controle , Infarto do Miocárdio/prevenção & controle , Inibidores da Agregação Plaquetária/uso terapêutico , Salicilatos/uso terapêutico , Prevenção Secundária , Acidente Vascular Cerebral/prevenção & controle , Idoso , Aspirina/efeitos adversos , Isquemia Encefálica/diagnóstico , Isquemia Encefálica/mortalidade , Doença da Artéria Coronariana/diagnóstico , Doença da Artéria Coronariana/mortalidade , Inibidores de Ciclo-Oxigenase/efeitos adversos , Feminino , Grécia , Hemorragia/induzido quimicamente , Humanos , Embolia Intracraniana/diagnóstico , Embolia Intracraniana/mortalidade , Masculino , Pessoa de Meia-Idade , Infarto do Miocárdio/diagnóstico , Infarto do Miocárdio/mortalidade , Inibidores da Agregação Plaquetária/efeitos adversos , Recidiva , Fatores de Risco , Salicilatos/efeitos adversos , Acidente Vascular Cerebral/diagnóstico , Fatores de Tempo , Resultado do Tratamento
2.
Surg Radiol Anat ; 32(1): 45-50, 2010 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-19690794

RESUMO

PURPOSE: The aim of the study was to evaluate the prevalence, length, depth, and location of myocardial bridging of the coronary arteries using 128-multi detector computed tomography coronary angiography. METHODS: The study cohort consisted of 875 patients who underwent coronary computed tomography angiography (CTA) for various indications. We evaluated the presence, length, and location of complete and incomplete bridging. In cases of complete bridging the thickness of the overlying muscle was also measured. RESULTS: From a total of 875 subjects, 184 subjects (21%) were found to a single myocardial bridge. Complete bridging was detected in 161 patients (18.4%) and incomplete bridging in 23 patients (2.6%). The coronary arteries involved were the mid portion of the left anterior descending artery (LAD) (67.9%), the distal portion of the LAD (28.8%), and the proximal portion of the LAD (3.2%). No myocardial bridging was detected in other arteries in our study. The mean length and maximum myocardial thickness overlying the complete bridging were 20.9 mm (range 8-32 mm) and 2.6 mm (range 1.2-5.3 mm), respectively. The mean length of the incomplete bridging was 17 mm (range 9-2.3 mm). CONCLUSIONS: Multi detector computed tomography is a reliable non-invasive modality for diagnosing myocardial bridging. The prevalence of myocardial bridging in this patient group was 21%. Our results are in agreement with those reported in pathologic studies, the gold standard for detecting this anomaly.


Assuntos
Ponte Miocárdica/diagnóstico por imagem , Adulto , Idoso , Idoso de 80 Anos ou mais , Angiografia Coronária , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Tomografia Computadorizada por Raios X
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...